A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors

导出原文传递

翻译打印收藏纠错

作者： Jones, Suzanne F. ^[1] ; Siu, Lillian L. ^[2] ; Bendell, Johanna C. ^[3] ; Cleary, James M. ^[4] ; Razak, Albiruni R. A. ^[5] ; Infante, Jeffrey R. ^[6] ; Pandya, Shuchi S. ^[7] ; Bedard, Philippe L. ; Pierce, Kristen J. ; Houk, Brett ; Roberts, W. Gregory ; Shreeve, S. Martin ; Shapiro, Geoffrey I.

作者单位： Dana Farber Canc Inst, Boston, MA 02115 USA ^[1] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA ^[2] Sarah Cannon Res Inst, Nashville, TN 37203 USA ^[3] Brigham & Womens Hosp, Boston, MA 02115 USA ^[4] Princess Margaret Canc Ctr, Toronto, ON, Canada ^[5] Pfizer Oncol, Groton, CT USA ^[6] Pfizer Oncol, La Jolla, CA USA ^[7]

关键词 Focal adhesion kinase Proline-rich tyrosine kinase-2 Dose-escalation study VS-6063 Defactinib

发布时间 2017-04-06

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交